Your browser doesn't support javascript.
loading
Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study.
Abtahi, Shahab; Pajouheshnia, Romin; Durán, Carlos E; Riera-Arnau, Judit; Gamba, Magdalena; Alsina, Ema; Hoxhaj, Vjola; Andersen, Morten; Bartolini, Claudia; Kristiansen, Sarah Brøgger; Brown, Jeremy; Hallgreen, Christine Erikstrup; Garcia-Poza, Patricia; Gardarsdottir, Helga; Gini, Rosa; Girardi, Anna; Holthuis, Emily; Huerta, Consuelo; Ibánez, Luisa; Limoncella, Giorgio; Martín-Pérez, Mar; Paoletti, Olga; Roberto, Giuseppe; Souverein, Patrick; Swart, Karin M A; Wing, Kevin; Sturkenboom, Miriam; Klungel, Olaf.
Afiliación
  • Abtahi S; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University (UU), David de Wiedgebouw, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
  • Pajouheshnia R; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University (UU), David de Wiedgebouw, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
  • Durán CE; Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
  • Riera-Arnau J; Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
  • Gamba M; Clinical Pharmacology Department, Hospital Universitari de la Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Alsina E; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University (UU), David de Wiedgebouw, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
  • Hoxhaj V; Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
  • Andersen M; Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
  • Bartolini C; Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Kristiansen SB; Agenzia Regionale di Sanità della Toscana (ARS), Firenze, Italy.
  • Brown J; Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Hallgreen CE; London School of Hygiene & Tropical Medicine (LSHTM), London, UK.
  • Garcia-Poza P; Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Gardarsdottir H; Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain.
  • Gini R; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University (UU), David de Wiedgebouw, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
  • Girardi A; Department of Clinical Pharmacy, UMCU, Utrecht, The Netherlands.
  • Holthuis E; Agenzia Regionale di Sanità della Toscana (ARS), Firenze, Italy.
  • Huerta C; Agenzia Regionale di Sanità della Toscana (ARS), Firenze, Italy.
  • Ibánez L; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
  • Limoncella G; Department of Public Health, Maternal and Child Health, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
  • Martín-Pérez M; Clinical Pharmacology Department, Hospital Universitari de la Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Paoletti O; Agenzia Regionale di Sanità della Toscana (ARS), Firenze, Italy.
  • Roberto G; Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain.
  • Souverein P; Agenzia Regionale di Sanità della Toscana (ARS), Firenze, Italy.
  • Swart KMA; Agenzia Regionale di Sanità della Toscana (ARS), Firenze, Italy.
  • Wing K; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University (UU), David de Wiedgebouw, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
  • Sturkenboom M; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
  • Klungel O; London School of Hygiene & Tropical Medicine (LSHTM), London, UK.
Drug Saf ; 46(7): 689-702, 2023 07.
Article en En | MEDLINE | ID: mdl-37294532
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ácido Valproico / Anticoncepción Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy País/Región como asunto: Europa Idioma: En Revista: Drug Saf Asunto de la revista: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ácido Valproico / Anticoncepción Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy País/Región como asunto: Europa Idioma: En Revista: Drug Saf Asunto de la revista: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos